- Everyday Urology™ – Oncology Insights
Journal: Everyday Urology™ – Oncology Insights
From the Editor
From the Desk of the Editor: Volume 2, Issue 2
Optimizing the patient clinical outcome (prolonging survival, preserving quality of life, and preventing complications) while avoiding excessive healthcare economic burden is tantamount to the overall improvement of the healthcare system. Certainly, combining an integrative, multidisciplinary approach, which can attain these aforementioned goals will align with the “Triple Aim”, which proposes that improving the U.S. health care system requires simultaneous pursuit of three aims: improving the experience of care, improving the health of populations, and reducing per capita costs of health care.
Neal Shore, MD, FACS
Neal Shore, MD, is an internationally recognized expert in systemic therapies for patients with advanced urologic cancers and innovative therapies to treat patients suffering from prostate enlargement symptoms. Dr. Shore was recently appointed President of the Large Urology Group Practice Association (LUGPA), which seeks to provide urologists with all the tools they need to effectively care for patients.
Dr. Shore is the Medical Director of the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 300 clinical trials, focusing mainly on prostate and bladder disease. Dr. Shore is a Certified Physician Investigator who has numerous publications in peer-reviewed journals and has lectured extensively on the treatment of prostate cancer and prostate enlargement. He serves on several industry advisory boards as well as academic and advocacy networks: including the Society Urologic Oncology Clinical Trials Consortium, Bladder Cancer Advocacy Network,and the Large Urology Group Practice Association.. Dr. Shore is the editor-in-chief of UroToday’s print publication, Everyday Urology- Oncology Insights.
In this issue
- Enhanced Recovery After Surgery, Radical Cystectomy and Urinary Diversion
- Assessment of Cardiovascular Risk With the Use of Androgen Deprivation Therapy for Prostate Cancer
- Radium-223:The Only Approved Targeted Alpha Therapy (TAT) in mCRPC- Outcomes, Opportunities and Lessons Learned